An $11 Billion Fund Dumps These 2 Stocks

Bobby Sankhagowit • 6 minute read
Reviewed by: Bobby Sankhagowit
Last updated Nov 17, 2026

Kittipong Jirasukhanont from PhonlamaiPhoto's Images, Nikada from Getty Images Signature via Canva

Key Takeaways

  • Atreides Management, an $11 billion fund, sold all of its Amphenol and Alphabet shares in the third quarter and more than doubled its stakes in Astera Labs and Meta Platforms.
  • The Alphabet exit isn’t a clean one, since the fund held Alphabet call options with $688 million of notional value at Sept. 30.
  • Analysts see more than 40% upside in both stocks the fund sold, and Amphenol’s average price target is at its high for the year after a record quarter.
  • Of the two stocks the fund sold, Amphenol looks like the better buy today.

Atreides Management sold every share it held of Amphenol (APH) and Alphabet (GOOGL) in the third quarter. That’s from its 13F for the quarter ended Sept. 30, filed Nov. 16. The firm manages $10.7 billion, and neither stock is among its 41 positions now.

In the same quarter, it more than doubled its stakes in Astera Labs (ALAB) and Meta Platforms (META), which are now its No. 2 and No. 3 positions. But the Alphabet sale isn’t what it looks like.

Atreides still has a big Alphabet bet

At June 30, Atreides held 488,296 Alphabet shares worth $175 million, or 1.6% of its 13F stocks. By Sept. 30, the shares were gone. But the same filing shows call options on Alphabet with $688 million of notional value, nearly four times what the shares were worth at June 30.

A 13F doesn’t say when a fund traded, what it paid or why. Still, it’s hard to call this a vote against Alphabet. The fund sold its shares and still had a lot riding on the stock at Sept. 30.

Analysts still see big upside in Alphabet

Alphabet is 31% below its 52-week high, and Wall Street hasn’t given up on it. The 58 analysts who cover it have an average price target of $400, 41% above the last close. That average has climbed over the past year, though it has come down from its peak:

Line chart from TIKR of Alphabet's analysts' consensus (mean) price target, $ per share, last year.
Alphabet (GOOGL): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

The average target was $317 a year ago and peaked at $433 in late July. Over the same year the stock has barely moved: it closed at $284, against $285 a year ago. It trades at about 21x forward earnings.

TIKR tracks 19 analysts on Amphenol. How many say “Buy”?

See the full breakdown of Buy, Hold, and Sell ratings on Amphenol, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See Amphenol’s Analyst Ratings

Amphenol posted a record quarter after the fund sold

Amphenol was the cleaner exit. At June 30, Atreides held 640,069 shares worth $113 million, or 1.0% of its 13F stocks, and the Sept. 30 filing shows no shares and no options.

In late October, Amphenol reported a record $10.2 billion quarter, raised its guidance and announced a new $4 billion buyback, and the stock jumped 7% that day. Analysts have been raising their targets all year:

Line chart from TIKR of Amphenol's analysts' consensus (mean) price target, $ per share, last year.
Amphenol (APH): analysts’ consensus (mean) price target, $ per share, last year (TIKR)

In a year, the average target has gone from $72.50 to $107, a 48% climb, and it hit its high for the year in early November. The stock is up 14% over the same stretch. The 19 analysts who cover Amphenol see 42% upside from here. The stock trades at about 22x forward earnings and sits 16% below its 52-week high.

It doubled down on Astera Labs and Meta

The same filing shows where Atreides added. At Sept. 30 it held 2.46 million Astera Labs shares, up 102% from June 30, worth $875 million, or 8.1% of its 13F stocks. Its Meta stake grew 117% to 872,413 shares worth $633 million (5.9%). On top of that, it held Meta call options with $1.38 billion of notional value.

Those bigger bets have had a rough start. Since Sept. 30, Astera Labs is down 43% and Meta is down 14%. Those are price changes from the quarter’s end, not the fund’s return, since we don’t know what it paid or whether it still holds the shares.

Other big funds don’t all agree, either. Whale Rock Capital, a firm managing nearly $13 billion, sold all 1.57 million of its Astera Labs shares by Sept. 30. On Meta, though, Atreides has company: JPMorgan picked it over Alphabet earlier this month. Meta trades at about 19x forward earnings, below its five-year average of about 21x.

If I could only buy one, it’d be Amphenol

The numbers back both stocks Atreides sold. I wouldn’t read much into the Alphabet sale, though, since at Sept. 30 the fund’s options on Alphabet had about four times the notional value of the shares it sold.

Amphenol is the one where analysts are getting more bullish. Its average target is at a one-year high, and the stock has risen far less than the target over the year. The risk is that analysts have already raised their targets a lot, so plenty of good news is in the Street’s math.

If I could only buy one of the two right now, it’d be Amphenol. Its results keep improving, and today’s price still leaves it room to run.

Of course, a 13F only shows where the fund stood on Sept. 30. Atreides’ next one, due in mid-February, will show whether it bought back into either stock.

So what is Amphenol stock actually worth?

TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what Amphenol could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.

Value Amphenol for free

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!

Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Sign Up for FREENo credit card required